Two simple solutions could help prevent postpartum hemorrhage

Two simple solutions could help prevent severe bleeding (postpartum hemorrhage) after cesarean delivery, suggests research presented at the ANESTHESIOLOGY® 2023 annual meeting.

Biogen scores breakthrough status for anti-rejection transplant medication

Biogen acquired felzartamab through the $1.15bn Human Immunology Biosciences (HI-Bio) acquisition in July 2024. Image credit: Tada Images / Shutterstock. The US Food and Drug

October 10, 2024

Why a British hospital, and not a drugmaker, is trying to get a rare disease therapy approved

LONDON — Claire Booth, a gene therapy researcher in London, had hoped that a biotech company would take her team’s work on an experimental medication

April 25, 2024

7 children developed blood cancer after Bluebird Bio gene therapy for rare neurological disease

Newly published data show that seven out of 67 children who received Bluebird Bio’s gene therapy for a devastating neurological disorder in clinical trials have

October 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.